 <h1>Xgeva Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>denosumab</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about denosumab. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Xgeva.</p><h2>In Summary</h2><p><b>Common side effects of Xgeva include:</b> dermatitis, eczema, and skin rash. <b>Other side effects include:</b> serious infection, and hypercholesterolemia.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to denosumab: subcutaneous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, denosumab (the active ingredient contained in Xgeva) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking denosumab:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>blistering, crusting, irritation, itching, or reddening of the skin</li>
<li>bloody or cloudy urine</li>
<li>cracked, dry, or scaly skin</li>
<li>difficult, burning, or painful urination</li>
<li>frequent urge to urinate</li>
<li>muscle or bone pain</li>
<li>pain in the arms or legs</li>
<li>rash</li>
<li>skin rash, encrusted, scaly, and oozing</li>
<li>swelling</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Arm or jaw pain</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>body aches or pain</li>
<li>chest pain or discomfort</li>
<li>chest tightness or heaviness</li>
<li>chills</li>
<li>confusion</li>
<li>congestion</li>
<li>cough</li>
<li>difficulty with breathing</li>
<li>difficulty with moving</li>
<li>dryness or soreness of the throat</li>
<li>ear congestion</li>
<li>fast or irregular heartbeat</li>
<li>fever</li>
<li>headache</li>
<li>hoarseness</li>
<li>joint pain</li>
<li>loss of voice</li>
<li>muscle cramps in the hands, arms, feet, legs, or face</li>
<li>muscle stiffness</li>
<li>numbness and tingling around the mouth, fingertips, hands, or feet</li>
<li>pain in the lower back, bottom, upper leg, or hips</li>
<li>painful blisters on the trunk of the body</li>
<li>pale skin</li>
<li>rapid weight gain</li>
<li>runny or stuffy nose</li>
<li>seizures</li>
<li>sneezing</li>
<li>stomach cramps</li>
<li>swollen joints</li>
<li>tender, swollen glands in the neck</li>
<li>tremor</li>
<li>trouble swallowing</li>
<li>troubled breathing with exertion</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
<li>voice changes</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Blood in the stool</li>
<li>change in bowel habits</li>
<li>clear or bloody discharge from the nipple</li>
<li>constipation</li>
<li>darkened urine</li>
<li>difficulty with eating</li>
<li>dimpling of the breast skin</li>
<li>indigestion</li>
<li>inverted nipple</li>
<li>itching, pain, redness, swelling, tenderness, or warmth on the skin</li>
<li>loss of appetite</li>
<li>lower back or side pain</li>
<li>lump in the breast or under the arm</li>
<li>lump or swelling in the abdomen or stomach</li>
<li>nausea</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>persistent crusting or scaling of the nipple</li>
<li>raised, firm, and bright red patches of the skin on the arm or leg</li>
<li>redness or swelling of the breast</li>
<li>sore on the skin of the breast that does not heal</li>
<li>stomach discomfort</li>
<li>unexplained weight loss</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Heavy feeling in the jaw</li>
<li>loose teeth</li>
<li>pain, swelling, or numbness in the mouth or jaw</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of denosumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Dizziness or lightheadedness</li>
<li>excess air or gas in the stomach or bowels</li>
<li>feeling of constant movement of self or surroundings</li>
<li>feeling of fullness</li>
<li>heartburn</li>
<li>lack or loss of strength</li>
<li>passing gas</li>
<li>redness, pain, itching, burning, swelling, or a lump under your skin where the shot was given</li>
<li>sensation of spinning</li>
<li>trouble sleeping</li>
<li>upper abdominal or stomach pain</li>
</ul><p>
<!-- end subcutaneous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to denosumab: subcutaneous solution</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Angina pectoris, atrial fibrillation<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Anaphylaxis, rash, urticaria, facial swelling, erythema<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (21%), cough (15%)</p>
<p><b>Common</b> (1% to 10%): Upper respiratory tract infection, pneumonia, pharyngitis, nasopharyngitis<sup>[Ref]</sup></p><h3>General</h3><p>The most commonly reported side effects were asthenia, fatigue, back pain, hypophosphatemia, hypocalcemia, and nausea.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (35%), arthralgia (14%), pain in extremity (12%)</p>
<p><b>Common</b> (1% to 10%): Musculoskeletal pain, bone pain, myalgia, spinal osteoarthritis</p>
<p><b>Rare</b> (less than 0.1%): Atypical femoral fractures</p>
<p><b>Frequency not reported</b>: Osteonecrosis of the jaw, atypical subtrochanteric and diaphysealfemoral fractures</p>
<p><b>Postmarketing reports</b>: Musculoskeletal pain including severe cases, multiple vertebral fractures following discontinuation of this drug<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypophosphatemia (32%), hypocalcemia (including fatal cases) (18%)</p>
<p><b>Common</b> (1% to 10%): Hypercholesterolemia</p>
<p><b>Postmarketing reports</b>: Severe symptomatic hypocalcemia, severe symptomatic hypercalcemia following treatment discontinuation<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Dermatitis (11%), eczema (11%), rash (11%)</p>
<p><b>Common</b> (1% to 10%): Pruritus, hyperhidrosis</p>
<p><b>Uncommon</b> (0.1% to 1%): Cellulitis</p>
<p><b>Postmarketing reports</b>: Cutaneous and mucosal lichenoid drug eruptions (e.g., lichen planus-like reactions), alopecia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (31%), diarrhea (20%)</p>
<p><b>Common</b> (1% to 10%): Upper abdominal pain, flatulence, gastroesophageal reflux disease, constipation, abdominal discomfort, tooth extraction</p>
<p><b>Uncommon</b> (0.1% to 1%): Pancreatitis, diverticulitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (13%)</p>
<p><b>Common</b> (1% to 10%): Vertigo, sciatica<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infections, cystitis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Anemia<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Postmarketing reports</b>: Marked elevation in serum PTH in patients with severe renal impairment (CrCl less than 30 mL/min) or receiving dialysis<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Receptor activator of nuclear factor kappa-B ligand (RANKL) is expressed on activated T and B lymphocytes and in lymph nodes; therefore, a RANKL inhibitor such as this drug may increase the risk of infection.  A study of postmenopausal women with osteoporosis (n=7808), has shown a higher incidence of nonfatal serious infections in those receiving this drug compared with placebo (4% vs 3.3%).  Hospitalizations due to serious infections in the abdomen (0.9% vs 0.7%), urinary tract (0.7% vs. 0.5%), ear (0.1% vs. 0%) and skin, including erysipelas and cellulitis (0.4% vs. less than 0.1%) were reported.  Endocarditis was reported in 3 patients receiving this drug and no placebo patients.  The incidence of infections resulting in death was 0.2% in both groups and the incidence of opportunistic infections was the same in both groups.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Herpes zoster, serious infections (nonfatal cases)</p>
<p><b>Uncommon</b> (0.1% to 1%): Serious Infections (fatal cases)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Cataracts<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): New malignancies </p>
<p><b>Uncommon</b> (0.1% to 1%): Basal cell carcinoma<sup>[Ref]</sup></p><p>New malignancies were reported in 4.8% of patients receiving this drug (placebo=4.3%); new malignancies included breast (0.9%), reproductive system (0.5%), and gastrointestinal system (0.9%).  A causal relationship to drug exposure has not been established.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Asthenia (45%), fatigue (45%)</p>
<p><b>Common</b> (1% to 10%): Peripheral edema</p>
<p><b>Uncommon</b> (0.1% to 1%): Ear infection<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Prolia (denosumab)." Amgen USA, Thousand Oaks, CA. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Xgeva (denosumab)." Amgen USA, Thousand Oaks, CA. </p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Xgeva vs Prolia. How do they compare?</li>
<li>How long should you take Xgeva for?</li>
<li>Is Xgeva a chemotherapy drug?</li>
<li>Does Xgeva cause bone pain?</li>
<li>Does Xgeva cause low blood pressure?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Xgeva (denosumab)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>7 Reviews</li>
<li>Drug class: miscellaneous bone resorption inhibitors</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Xgeva &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Prolia</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Osteolytic Bone Lesions of Multiple Myeloma</li>
<li>Giant Cell Tumor of Bone</li>
<li>Osteolytic Bone Metastases of Solid Tumors</li>
<li>Hypercalcemia of Malignancy</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to denosumab: subcutaneous solution</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Angina pectoris, atrial fibrillation<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Anaphylaxis, rash, urticaria, facial swelling, erythema<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (21%), cough (15%)</p><p><b>Common</b> (1% to 10%): Upper respiratory tract infection, pneumonia, pharyngitis, nasopharyngitis<sup>[Ref]</sup></p><h3>General</h3><p>The most commonly reported side effects were asthenia, fatigue, back pain, hypophosphatemia, hypocalcemia, and nausea.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (35%), arthralgia (14%), pain in extremity (12%)</p><p><b>Common</b> (1% to 10%): Musculoskeletal pain, bone pain, myalgia, spinal osteoarthritis</p><p><b>Rare</b> (less than 0.1%): Atypical femoral fractures</p><p><b>Frequency not reported</b>: Osteonecrosis of the jaw, atypical subtrochanteric and diaphysealfemoral fractures</p><p><b>Postmarketing reports</b>: Musculoskeletal pain including severe cases, multiple vertebral fractures following discontinuation of this drug<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypophosphatemia (32%), hypocalcemia (including fatal cases) (18%)</p><p><b>Common</b> (1% to 10%): Hypercholesterolemia</p><p><b>Postmarketing reports</b>: Severe symptomatic hypocalcemia, severe symptomatic hypercalcemia following treatment discontinuation<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Dermatitis (11%), eczema (11%), rash (11%)</p><p><b>Common</b> (1% to 10%): Pruritus, hyperhidrosis</p><p><b>Uncommon</b> (0.1% to 1%): Cellulitis</p><p><b>Postmarketing reports</b>: Cutaneous and mucosal lichenoid drug eruptions (e.g., lichen planus-like reactions), alopecia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (31%), diarrhea (20%)</p><p><b>Common</b> (1% to 10%): Upper abdominal pain, flatulence, gastroesophageal reflux disease, constipation, abdominal discomfort, tooth extraction</p><p><b>Uncommon</b> (0.1% to 1%): Pancreatitis, diverticulitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (13%)</p><p><b>Common</b> (1% to 10%): Vertigo, sciatica<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infections, cystitis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Anemia<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Postmarketing reports</b>: Marked elevation in serum PTH in patients with severe renal impairment (CrCl less than 30 mL/min) or receiving dialysis<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Receptor activator of nuclear factor kappa-B ligand (RANKL) is expressed on activated T and B lymphocytes and in lymph nodes; therefore, a RANKL inhibitor such as this drug may increase the risk of infection.  A study of postmenopausal women with osteoporosis (n=7808), has shown a higher incidence of nonfatal serious infections in those receiving this drug compared with placebo (4% vs 3.3%).  Hospitalizations due to serious infections in the abdomen (0.9% vs 0.7%), urinary tract (0.7% vs. 0.5%), ear (0.1% vs. 0%) and skin, including erysipelas and cellulitis (0.4% vs. less than 0.1%) were reported.  Endocarditis was reported in 3 patients receiving this drug and no placebo patients.  The incidence of infections resulting in death was 0.2% in both groups and the incidence of opportunistic infections was the same in both groups.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Herpes zoster, serious infections (nonfatal cases)</p><p><b>Uncommon</b> (0.1% to 1%): Serious Infections (fatal cases)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Cataracts<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): New malignancies </p><p><b>Uncommon</b> (0.1% to 1%): Basal cell carcinoma<sup>[Ref]</sup></p><p>New malignancies were reported in 4.8% of patients receiving this drug (placebo=4.3%); new malignancies included breast (0.9%), reproductive system (0.5%), and gastrointestinal system (0.9%).  A causal relationship to drug exposure has not been established.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Asthenia (45%), fatigue (45%)</p><p><b>Common</b> (1% to 10%): Peripheral edema</p><p><b>Uncommon</b> (0.1% to 1%): Ear infection<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Prolia (denosumab)." Amgen USA, Thousand Oaks, CA. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Xgeva (denosumab)." Amgen USA, Thousand Oaks, CA. </p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Xgeva vs Prolia. How do they compare?</li>
<li>How long should you take Xgeva for?</li>
<li>Is Xgeva a chemotherapy drug?</li>
<li>Does Xgeva cause bone pain?</li>
<li>Does Xgeva cause low blood pressure?</li>
</ul><h2>More about Xgeva (denosumab)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>7 Reviews</li>
<li>Drug class: miscellaneous bone resorption inhibitors</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Xgeva &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Osteolytic Bone Lesions of Multiple Myeloma</li>
<li>Giant Cell Tumor of Bone</li>
<li>Osteolytic Bone Metastases of Solid Tumors</li>
<li>Hypercalcemia of Malignancy</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>